ARCHIVES

FDA Approval of Abraxane Sets Stage for Competition Between Taxane Drugs. Abraxane a Nanotechnology Drug? Sponsor Says Yes, FDA Says.

This article is from The Cancer Letter archive.

Vol. 31 No. 02 | January 14, 2005

Download PDF Visit The Full Archive

Related Articles

Genetic Test Identifies Patients With High Risk of Mortality

November 30, 2012

In Brief: Elion, Schein, Johnson Head Societies; Phillips, Salmon Elected; McIntire, Pistenma to Leave NCI

June 3, 1983

Carcinogenesis Program Direction Changes Near for Extramural research; Workshop Topics Listed

April 22, 1977

Waldmann, Columbia, Netherland, Receive Bristol-Myers Awards

April 17, 1992

“Mind Boggling” Results Reported In Trials Using 3-Drug Combination For Breast Cancer

October 10, 1975

Insulin For Diabetes Increases Risk Of Colorectal Cancer

December 31, 2004